EUCTR2015-004656-22-ES进行中（未招募）1 期
Pilot study of the [18F]THK-5351 positron emission tomography (PET) tracer in different tauopathies.
Institut de Recerca HSCSP0 个研究点目标入组 80 人开始时间: 2016年2月24日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Inclusion criteria for patients: (1) Men and women over eighteen years-old; (2) evaluated at the Memory unit of the Hospital de la Santa Creu i Sant Pau; (3) that meet current clinical criteria for Alzheimer disease dementia, mild cognitive impairment due to Alzheimer disease, DS related dementia, nfPPA, bvFTD, PSP and CBD; (4) and given written informed consent.
- •Inclusion criteria for healthy controls: (1) Men and women over eighteen years old; (2) currently enrolled in other clinical studies of the Memory unit at the Hospital de la Santa Creu i Sant Pau; (3) without cognitive complaints; (4) a normal performance on neuropsychological evaluation (adjusted by age and education); (5) and given written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •General exclusion criteria: (1) Non-compliance of inclusion criteria; (2) Diagnosis of major depression; (3) Previous stroke; (4) Inability to perform lumbar puncture, magnetic resonance imaging or neuropsychological evaluation.
研究者
相似试验
已完成
1 期
A Phase I [18F]THK-5351 Positron Emission Tomography Study in Healthy Subjects and Alzheimer's DiseaseAlzheimer DiseaseNCT03112096Asan Foundation12
进行中（未招募）
1 期
Detection of Prostate Cancer Lesions with Imaging Tracer for Positron Emission Tomography in Patients who have previously been treated for Prostate CancerSuspicion of prostate cancer recurrence or persistence after previous definitive treatment, based on American Society for Radiation Oncology (ASTRO) criteria of 3 consecutive PSA rises and/or ASTRO/Phoenix criteria of PSA nadir above 2.0 ng/mL after radiotherapy or cryotherapy and/or greater than 0.2 ng/mL after prostatectomyMedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10036911Term: Prostate cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-004235-24-NLABX GmbH70
已完成
1 期
Validation of the new Positron Emissions Tomography (PET) Radioligand (+)-[18F]-Flubatine for Imaging of Nicotinic Acetylcholine Receptors (nAChR) in Alzheimer’s Dementiahealthy volunteersF00Dementia in Alzheimer diseaseDRKS00005819niversität Leipzig34
已完成
不适用
The study on the usefulness of positron emission tomography wtih [11C]PBB3Alzheimer's disease Psychotic disorders Mood disorders Traumatic brain injury EpilepsyJPRN-UMIN000014785ippon Medical School120
已完成
2 期
Phase II study of 18 F fluorothymidine Positron Emission Tomography (FLT-PET) in the follow up of glioblastoma multiforme (GBM) patients treated with combined radiotherapie and chemotherapybraintumor10029211glioblastoma multiformeNL-OMON38320niversitair Medisch Centrum Groningen30